Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Clin Psychol Med Settings ; 25(1): 11-19, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29264730

RESUMEN

Barriers for renal transplant patients to immunosuppressant medication adherence are poorly understood, despite the high rate and toll of non-adherence. We sought to assess factors that contribute to barriers to immunosuppressive medication adherence in an ethnically diverse sample of 312 renal transplant patients recruited from three transplant centers across New York City. Transplant patients who were at least 6 months post-transplant completed questionnaires while waiting for their medical appointment. Ethnic differences were observed on barriers to immunosuppressant adherence. Black and Hispanic participants reported significantly more barriers to adherence compared to Caucasian participants. Differences in perception about the potential harm and necessity of immunosuppressant medications also were present. Using hierarchical multiple regression, age and income were significant predictors of reported barriers to adherence, even while controlling for ethnicity. The most robust predictor of reported barriers was the perception of the medication cost-benefit differential, i.e., the balance between concerns about immunosuppressant medications and their perceived helpfulness (B = - 0.5, p < .001), indicating that varying beliefs about the medication's necessity and utility rather than ethnicity explain the differences in barriers to medication adherence. Future interventions targeting non-adherence should aim to reduce the barriers to adherence by addressing perceived risks and benefits of taking immunosuppressant medication.


Asunto(s)
Etnicidad/psicología , Conocimientos, Actitudes y Práctica en Salud , Inmunosupresores/administración & dosificación , Trasplante de Riñón/psicología , Cumplimiento de la Medicación/psicología , Cumplimiento de la Medicación/estadística & datos numéricos , Estudios Transversales , Etnicidad/estadística & datos numéricos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ciudad de Nueva York , Encuestas y Cuestionarios
2.
J Nephrol ; 26(2): 323-30, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22684651

RESUMEN

BACKGROUND: Uremia has long been associated with cognitive deficits. This study explored the importance of the time of measurement of neurocognitive functioning, by directly comparing changes in neurocognitive functioning from immediately after hemodialysis treatment to immediately before treatment. METHODS: Twenty-five hemodynamically stable hemodialysis patients and 6 peritoneal dialysis controls completed 2 computer-based assessment batteries (ANAM), one immediately before dialysis and the second upon completion of that dialysis session. Paired sample t-tests were used to compare postdialysis with predialysis neurocognitive functioning scores for both a composite measure of global functioning and the neurocognitive subtests. RESULTS: There was significant improvement in global neuropsychological functioning from predialysis to postdialysis (t (24) = -7.5, p<0.001), showing an average of 18% improvement in the hemodialysis group, with no significant change in the peritoneal dialysis group. CONCLUSION: This study suggests that computer-based testing can offer information on the cognitive fluctuations of medically complex populations and suggests that the end of the session may be a better time to discuss important and complex health messages with hemodialysis patients. It further implies that some of the neurocognitive impairment that is associated with end-stage renal disease is a consequence of uremia and is improved by hemodialysis.


Asunto(s)
Trastornos del Conocimiento/etiología , Cognición , Fallo Renal Crónico/terapia , Diálisis Renal , Uremia/terapia , Adulto , Estudios de Casos y Controles , Distribución de Chi-Cuadrado , Trastornos del Conocimiento/diagnóstico , Trastornos del Conocimiento/psicología , Femenino , Humanos , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/psicología , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Proyectos Piloto , Factores de Tiempo , Resultado del Tratamiento , Uremia/etiología , Uremia/psicología
3.
Hemodial Int ; 16(3): 387-93, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22469200

RESUMEN

The scientific evaluation of depression's impact on mortality in hemodialysis (HD) patients has yielded mixed results, with the more recent, more rigorous studies detecting a significant relationship. In this study, 130 HD patients from an urban North American hospital were evaluated for depressive affect and then observed for up to 5 years. In a corrected Cox regression model, which held constant age, gender, dialysis vintage, illness severity and diabetic status, depressive affect emerged as a modest but significant predictor of mortality (relative risk = 1.05, 95% confidence interval = 1.01-1.08). When the subjects were divided according to depressive affect severity, those with severe depressive affect had significantly shorter time to death (ß = 0.452, P = 0.044). In a subgroup of 85 subjects, self-reported medication adherence was also predictive of mortality, with higher rates of nonadherence being associated with increased mortality risk. This paper lends support to the burgeoning literature on depression and reduced survival in HD populations, as well as begins the investigation of understanding the underlying mechanisms.


Asunto(s)
Depresión/psicología , Fallo Renal Crónico/psicología , Fallo Renal Crónico/terapia , Cooperación del Paciente/psicología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA